Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04363684 · ClinicalTrials.gov registry record

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

A clinical trial of Amyotrophic Lateral Sclerosis and Progressive Supranuclear Palsy (PSP), sponsored by Mayo Clinic.

Recruiting
Registry status
2,100
Enrollment target
20
Study locations

NCT04363684 is a study of Amyotrophic Lateral Sclerosis and Progressive Supranuclear Palsy (PSP) that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 2,100 participants, above the 877-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (139% higher). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04363684, a study of Amyotrophic Lateral Sclerosis and Progressive Supranuclear Palsy (PSP), is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
2,100 participants
Enrollment target
20
Study locations

Study Summary

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

Conditions Studied

Amyotrophic Lateral Sclerosis Progressive Supranuclear Palsy (PSP) Corticobasal Degeneration (CBD) Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Semantic Variant Primary Progressive Aphasia (svPPA) C9orf72 Frontotemporal Lobar Degeneration (FTLD) Behavioral Variant Frontotemporal Dementia (bvFTD) FTD With Amyotrophic Lateral Sclerosis (FTD/ALS) Oligosymptomatic PSP (oPSP)

Study Locations (20)

California

  • University of California, Los Angeles - Los Angeles
  • University of California, San Diego - San Diego
  • University of California San Francisco - San Francisco

Maryland

  • Johns Hopkins University - Baltimore
  • NIH - Bethesda

New York

  • Mount Sinai - New York
  • Columbia University - New York

Alabama

  • University of Alabama Birmingham - Birmingham

Colorado

  • University of Colorado Denver - Denver

Florida

  • Mayo Clinic Florida - Jacksonville

Georgia

  • Emory University - Atlanta

Illinois

  • Northwestern University - Chicago

Trial Details

FieldValue
Enrollment Target 2,100 participants
Start Date 2020-03-01
Est. Completion 2026-06-30

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04363684

The ClinicalTrials.gov registry entry for NCT04363684 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 877-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (139% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT04363684 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Maryland, New York.

Frequently Asked Questions

What is clinical trial NCT04363684 about?

NCT04363684 is a clinical study titled "ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)". ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

What is the current status of trial NCT04363684?

This trial is currently recruiting. The enrollment target is 2,100 participants. The study started on 2020-03-01. Estimated completion is 2026-06-30.

What conditions does trial NCT04363684 study?

This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis, Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Semantic Variant Primary Progressive Aphasia (svPPA).

Who is sponsoring clinical trial NCT04363684?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04363684 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Amyotrophic Lateral Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Amyotrophic Lateral Sclerosis

All registered trials for this condition

Progressive Supranuclear Palsy (PSP)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.